Although 2011 revenue was up overall, Nordion is anticipating a decline in its reactor isotopes revenue for fiscal year 2012. The company expects volumes of molybdenum-99 to remain the same, but anticipates competition will drive prices down. Nordion estimates 2012 quarterly revenue for cyclotron isotopes to be at $3.5 million per quarter.

Related Summaries